1-2 of 2 results for subject:"MGI Tech"
Librarians' tools
- Search time
- 0.174 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:"MGI Tech"
- We searched for
- subject_t:"MGI Tech" OR subject_t:MGI OR subject_ses:524399
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, if he will exclude (a) BGI Group, (b) MGI Tech and (c) other state-linked genomics companies blacklisted by the United States from public sector health bodies.
To ask the Secretary of State for Health and Social Care, if he will exclude (a) BGI Group, (b) MGI Tech and (c) other state-linked genomics companies blacklisted by the United States from public sector health bodies.
The Government continues to review the evolving national security risks in the life sciences sector, including engaging with partners and allies, while ensuring that the United Kingdom is at the forefront of innovation.
The Procurement Act will come into force in 2025 and will include a Debarment Review Service, which aims to safeguard public procurement from suppliers deemed to pose a risk. As with all national security risks, there will be engagement with colleagues across Cabinet and Parliament to ensure we maintain a robust approach to managing these risks as they evolve.
To ask the Secretary of State for Health and Social Care, whether he has had discussions with (a) Cabinet colleagues, (b) Genomics England, (c) UK Biobank and (d) NIHR BioResource on (i) BGI Group, (ii) MGI Tech and (iii) other state-linked genomics companies blacklisted by the USA.
To ask the Secretary of State for Health and Social Care, whether he has had discussions with (a) Cabinet colleagues, (b) Genomics England, (c) UK Biobank and (d) NIHR BioResource on (i) BGI Group, (ii) MGI Tech and (iii) other state-linked genomics companies blacklisted by the USA.
Through the delivery of the UK Biological Security Strategy, the Government is committed to ensuring the United Kingdom is resilient to a spectrum of biological threats, as well as being a world leader in innovation. As part of this strategy, the Government is undertaking a programme of work to assess how we can minimise the risks from biological data to protect our burgeoning bioeconomy and build confidence in sharing personal data, to improve health outcomes in the UK and across the world.
Department officials are working closely with UK Biobank, Genomics England, and the National Institute for Health and Care Research Bioresource on this programme of work, and there will be continued engagement with my Cabinet colleagues.